NiKem Research Srl Enters Into Research Service Agreement with InterMune, Inc.
Advertisement
NiKem Research Srl, an Italian drug discovery service provider, announced that it has entered into a Research Service Agreement with InterMune, Inc. Under the terms of the agreement, NiKem will, in the next 12 months, use its medicinal chemistry and early ADMET/PK platform and expertise to design, synthesize and profile drug-like compounds aimed towards specific, undisclosed pulmonology targets of interest for InterMune. Financial terms of the agreement were not disclosed.
According to the company, by pursuing this business opportunity with InterMune, NiKem Research further diversifies its client portfolio in Europe, the United States and Australia, now comprising large pharmaceutical corporations, small biotechs and a number of medium-sized companies.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Prosensa Advances Three Exon Skipping Candidates for Duchenne Muscular Dystrophy into the Next Development Stage - Prosensa to receive up to £27M in development and milestone payments from GSK
